eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
4/2024
vol. 19
 
Poleć ten artykuł:
Udostępnij:
Artykuł oryginalny

Ophthalmological manifestations in inflammatory bowel disease under the watchful eye of a gastroenterologist from a tertiary centre

Konrad Lewandowski
1
,
Magdalena Kaniewska
1
,
Katarzyna Karłowicz
1
,
Martyna Więcek
1
,
Edyta Tulewicz-Marti
1
,
Piotr Celmer
2
,
Małgorzata Frankowska
2
,
Joanna Sempińska-Szewczyk
2
,
Grażyna Rydzewska
1, 3

  1. Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Inferior and Administration, Warsaw, Poland
  2. Department of Ophthalmology, National Medical Institute of the Ministry of the Inferior and Administration, Warsaw, Poland
  3. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Gastroenterology Rev 2024; 19 (4): 397–407
Data publikacji online: 2024/11/13
Plik artykułu:
Pobierz cytowanie
 
Metryki PlumX:
 
1. Łodyga M, Eder P, Gawron-Kiszka M, et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2021; 16: 257-96.
2. Eder P, Łodyga M, Gawron-Kiszka M, et al. Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2023; 18: 1-42.
3. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022; 16: 2-17.
4. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020; 14: 4-22.
5. Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis 2023; 17: 827-54.
6. Migliorisi G, Vella G, Dal Buono A, et al. Ophthalmological manifestations in inflammatory bowel diseases: keep an eye on it. Cells 2024; 13: 142.
7. Evans P, Pardi D. Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed 2007; 9: 55.
8. Mendoza J, Lana R, Taxonera C, et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Med Clin (Barc) 2005; 125: 297-300.
9. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-36.
10. Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. ScientificWorldJournal 2015; 2015: 438402.
11. Mintz R, Feller E, Bahr R, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 135-9.
12. Williams H, Walker D, Orchard T. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008; 10: 597-605.
13. Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol 2016; 30: 304-15.
14. Girardin M, Waschke K, Seidman E. A case of acute loss of vision as the presenting symptom of Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 695-8.
15. Santeford A, Wiley L, Park S, et al. Impaired autophagy in macrophages promotes inflammatory eye disease. Autophagy 2016; 12: 1876-85.
16. Marticorena-Álvarez P, Chaparro M, Pérez-Casas A, et al. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn’s disease. J Crohns Colitis 2012; 6: 950-3.
17. Chan J, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol 2010; 248: 283-7.
18. Puli S, Benage D. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn’s disease. Am J Gastroenterol 2003; 98: 939-40.
19. Veerappan S, Kennedy M, O’Morain CA, et al. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2008; 20: 588-9.
20. Cherian A, Soumya C, Iype T, et al. Posterior reversible encephalopathy syndrome with PLEDsplus due to mesalamine. J Neurosci Rural Pract 2014; 5: 72-5.
21. Crohn B. Ocular lesions complicating ulcerative colitis. Am J Med Sci 1925; 169: 260-7.
22. Katsanos A, Asproudis I, Katsanos K, et al. Orbital and optic nerve complications of inflammatory bowel disease. J Crohns Colitis 2013; 7: 683-93.
23. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 9: 2300-7.
24. Ruiz Serrato A, Marín García D, Guerrero León M, et al. Palpebral ptosis, a rare ocular manifestation of Crohn’s disease. Arch Soc Esp Oftalmol 2013; 88: 323-6.
25. Karlinger K, Györke T, Makö E, et al. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000; 35: 154-67.
26. Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol 2014; 20: 17463-7.
27. Watson P, Young R. Scleral structure, organisation and disease. A review. Exp Eye Res 2004; 78: 609-23.
28. McGrath J, McDonald J, Macdonald J. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2004; 4: CD004722.
29. Thomas G, Rhodes J, Green J. Inflammatory bowel disease and smoking: a review. Am J Gastroenterol 1998; 93: 144-9.
30. Karmiris K, Avgerinos A, Tavernaraki A, et al. Prevalence and characteristics of extraintestinal manifestations in a large cohort of greek patients with inflammatory bowel disease. J Crohns Colitis 2016; 10: 429-36.
31. Bandyopadhyay D, Bandyopadhyay S, Ghosh P, et al. Extraintestinal manifestations in inflammatory bowel disease: prevalence and predictors in Indian patients. Indian J Gastroenterol 2015; 34: 387-94.
32. Santeford A, Wiley LA, Park S, et al. Impaired autophagy in macrophages promotes inflammatory eye disease. Autophagy 2016; 12: 1876-85.
33. Lin P, Tessler HH, Goldstein DA. Family history of inflammatory bowel disease in patients with idiopathic ocular inflammation. Am J Ophthalmol 2006; 141: 1097-104.
34. Manser CN, Borovicka J, Seibold F, et al. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J 2016; 4: 281-7.
35. Felekis T, Katsanos K, Kitsanou M, et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis 2009; 15: 29-34.
36. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44: 1-13.
37. Lanna CC, Ferrari Mde L, Rocha SL, et al. A cross-sectional study of 130 Brazilian patients with Crohn’s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol 2008; 27: 503-9.
38. Verbraak FD, Schreinemachers MC, Tiller A, et al. Prevalence of subclinical anterior uveitis in adult patients with inflammatory bowel disease. Br J Ophthalmol 2001; 85: 219-21.
39. Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv Ophthalmol 2003; 48: 663-76.
40. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34.
41. Salmon JF, Wright JP, Murray AD. Ocular inflammation in Crohn’s disease. Ophthalmology 1991; 98: 480-4.
42. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
43. Tappeiner C, Dohrmann J, Spital G, et al. Multifocal posterior uveitis in Crohn’s disease. Graefes Arch Clin Exp Ophthalmol 2007; 245: 457-9.
44. Malekzadeh MM, Vahedi H, Gohari K, et al. Emerging epidemic of inflammatory bowel disease in a middle-income country: a nation-wide study from Iran. Arch Iran Med 2016; 19: 2-15.
45. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10: 207-14.
46. Roberts H, Rai SN, Pan J, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking. Digestion 2014; 90: 122-9.
47. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2024; 18: 1-37.
48. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-9.
49. Uniken Venema WT, Voskuil MD, Dijkstra G, et al. The genetic background of inflammatory bowel disease: from correlation to causality. J Pathol 2017; 241: 146-58.
50. Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet 2017; 389: 1741-55.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
© 2024 Termedia Sp. z o.o.
Developed by Bentus.